192 related articles for article (PubMed ID: 21862211)
1. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Chou YW; Chaturvedi NK; Ouyang S; Lin FF; Kaushik D; Wang J; Kim I; Lin MF
Cancer Lett; 2011 Dec; 311(2):177-86. PubMed ID: 21862211
[TBL] [Abstract][Full Text] [Related]
2. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
Chuang TD; Chen SJ; Lin FF; Veeramani S; Kumar S; Batra SK; Tu Y; Lin MF
J Biol Chem; 2010 Jul; 285(31):23598-606. PubMed ID: 20498373
[TBL] [Abstract][Full Text] [Related]
3. Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.
Chou YW; Lin FF; Muniyan S; Lin FC; Chen CS; Wang J; Huang CC; Lin MF
Cell Biosci; 2015; 5():38. PubMed ID: 26185616
[TBL] [Abstract][Full Text] [Related]
4. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
5. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
[TBL] [Abstract][Full Text] [Related]
6. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
7. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.
Witt D; Burfeind P; von Hardenberg S; Opitz L; Salinas-Riester G; Bremmer F; Schweyer S; Thelen P; Neesen J; Kaulfuss S
Carcinogenesis; 2013 May; 34(5):1115-24. PubMed ID: 23349020
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
Mawatari T; Ninomiya I; Inokuchi M; Harada S; Hayashi H; Oyama K; Makino I; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2015 Dec; 47(6):2073-81. PubMed ID: 26497673
[TBL] [Abstract][Full Text] [Related]
11. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
15. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
17. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells.
Luo Z; Wang Z; He X; Liu N; Liu B; Sun L; Wang J; Ma F; Duncan H; He W; Cooper P
Int Endod J; 2018 Jul; 51(7):767-778. PubMed ID: 28375564
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.
Peng ZH; Kopeček J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1928-33. PubMed ID: 24656564
[TBL] [Abstract][Full Text] [Related]
19. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
20. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
